However, for total testosterone on triple negative breast cancer, estimates were consistent with a reduced risk (OR = 0.91, 95% CI:0.81, 1.03) while there was little evidence for an effect on HER2-Enriched breast cancer (OR = 0.98, 95% CI:0.81, 1.18). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.